 Anemia is a common complication in patients with advanced heart failure and chronic kidney disease, and it can worsen their prognosis. Researchers have been looking for ways to treat this comorbidity, including targeted hemoglobin therapeutics and novel drugs like hypoxia-inducible factor-prolyl hydroxylase domain inhibitors and hepsidin antagonists. These approaches could help improve outcomes for patients with cardiorenal anemia syndrome. This article was authored by Ona Nicoleta-Boligafinus, Ancawatu, Daniella Maria-Tanas, and others.